Change-of-Direction Repeated Sprints in Adolescent Female Basketball Players
29 juillet 2026 mis à jour par: Engin Güneş Atabaş, Pamukkale University
Effects of Changes of Direction on Repeated-Sprint Performance, Perceived Exertion, and Acute Cardiovascular Responses in Adolescent Female Basketball Players: A Randomized Crossover Study
The purpose of this randomized crossover study was to compare the acute effects of repeated-sprint protocols incorporating different numbers of 180-degree changes of direction in adolescent female basketball players.
Twenty participants completed three exercise conditions in a randomized, counterbalanced order: 10 × 15-m linear sprints, 10 × 15-m sprints incorporating one 180-degree change of direction, and 10 × 15-m sprints incorporating two 180-degree changes of direction.
Each sprint was followed by 30 seconds of passive recovery.
Sprint performance, perceived exertion, heart rate, peripheral oxygen saturation, and systolic and diastolic blood pressure were assessed.
The study examined whether increasing the number of changes of direction affected repeated-sprint performance and acute perceptual and cardiovascular responses.
Aperçu de l'étude
Statut
Complété
Les conditions
Description détaillée
This was an acute, randomized, counterbalanced, three-condition crossover study in which each participant completed all experimental conditions and served as her own control.
Following a standardized warm-up, participants completed one of three repeated-sprint protocols during each experimental condition: 10 × 15-m linear sprints without a change of direction, 10 × 15-m sprints incorporating one 180-degree change of direction, or 10 × 15-m sprints incorporating two 180-degree changes of direction. A 30-second passive recovery period was provided between repetitions. Total sprint distance, number of repetitions, and recovery duration were standardized across the three conditions; only the number of changes of direction differed.
Sprint times were recorded using electronic timing gates. Best, average, and worst sprint times were determined, and sprint decrement and the change from best to worst performance were calculated. Rating of perceived exertion was recorded after each protocol. Heart rate, peripheral oxygen saturation, and systolic and diastolic blood pressure were assessed immediately before and after each condition.
The experimental conditions were compared to determine whether increasing the number of 180-degree changes of direction altered absolute repeated-sprint performance, performance maintenance, perceived exertion, or immediate cardiovascular responses.
Type d'étude
Interventionnel
Inscription (Réel)
20
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Pamukkale
-
Denizli, Pamukkale, Turquie (Türkiye), 20000
- Pamukkale University Sports Sciences and Technology Research and Application Center
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
Accepte les volontaires sains
Oui
La description
Inclusion Criteria:
- Female basketball players aged 16-18 years.
- Currently competing in the U16 or U18 basketball leagues in Denizli, Türkiye.
- At least two years of structured basketball training experience.
- Regular participation in at least three training sessions and one official match per week.
- No injury or illness that could prevent maximal sprint performance.
Exclusion Criteria:
- Reporting an injury before testing that could prevent maximal sprint performance.
- Failure to attend all testing sessions or complete all three experimental conditions.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Sequence 1: Linear-One-COD-Two-COD
Participants assigned to Sequence 1 completed the linear repeated-sprint condition during the first experimental session, the one-COD condition during the second session, and the two-COD condition during the third session.
Consecutive sessions were separated by at least 48 hours.
|
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m linear sprints without a change of direction.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m repeated sprints.
Each repetition consisted of 7.5 m of forward sprinting followed by one 180-degree change of direction and a 7.5-m return sprint.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m repeated sprints.
Each repetition consisted of three consecutive 5-m sections and incorporated two 180-degree changes of direction.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
|
|
Expérimental: Sequence 2: One-COD-Two-COD-Linear
Participants assigned to Sequence 2 completed the one-COD repeated-sprint condition during the first experimental session, the two-COD condition during the second session, and the linear condition during the third session.
Consecutive sessions were separated by at least 48 hours.
|
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m linear sprints without a change of direction.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m repeated sprints.
Each repetition consisted of 7.5 m of forward sprinting followed by one 180-degree change of direction and a 7.5-m return sprint.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m repeated sprints.
Each repetition consisted of three consecutive 5-m sections and incorporated two 180-degree changes of direction.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
|
|
Expérimental: Sequence 3: Two-COD-Linear-One-COD
Participants assigned to Sequence 3 completed the two-COD repeated-sprint condition during the first experimental session, the linear condition during the second session, and the one-COD condition during the third session.
Consecutive sessions were separated by at least 48 hours.
|
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m linear sprints without a change of direction.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m repeated sprints.
Each repetition consisted of 7.5 m of forward sprinting followed by one 180-degree change of direction and a 7.5-m return sprint.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m repeated sprints.
Each repetition consisted of three consecutive 5-m sections and incorporated two 180-degree changes of direction.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Average Sprint Time
Délai: During the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
The mean completion time of the 10 maximal 15-m sprint repetitions, recorded using Witty electronic timing gates and expressed in seconds.
The outcome was calculated separately for the linear, one-COD, and two-COD repeated-sprint conditions.
|
During the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Best Sprint Time
Délai: During the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
The fastest completion time (lowest value) among the 10 maximal 15-m sprint repetitions, recorded using Witty electronic timing gates and expressed in seconds.
The outcome was determined separately for the linear, one-COD, and two-COD repeated-sprint conditions.
|
During the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Worst Sprint Time
Délai: During the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
The slowest completion time (highest value) among the 10 maximal 15-m sprint repetitions, recorded using Witty electronic timing gates and expressed in seconds.
The outcome was determined separately for the linear, one-COD, and two-COD repeated-sprint conditions.
|
During the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Sprint Decrement
Délai: Calculated from the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
The percentage reduction in performance across the 10 maximal sprint repetitions.
Sprint decrement was calculated separately for each experimental condition using the following formula: Sdec (%) = ([sum of the 10 sprint times / (best sprint time × 10)] - 1) × 100.
Higher values indicate a greater decline in repeated-sprint performance.
|
Calculated from the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Worst-to-Best Decrement
Délai: Calculated from the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
The percentage difference between the fastest and slowest sprint repetitions, calculated separately for each experimental condition using the following formula: [(worst sprint time - best sprint time) / best sprint time] × 100.
Higher values indicate a greater decline from the best to the worst performance.
|
Calculated from the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Rating of Perceived Exertion
Délai: Immediately after completion of the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
Perceived exertion was assessed using the Borg category-ratio scale ranging from 0 to 10, where 0 represents rest and 10 represents maximal exertion.
Participants rated the overall difficulty of each completed repeated-sprint condition.
|
Immediately after completion of the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Heart Rate
Délai: Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
Heart rate was measured using a Soulfix fingertip pulse oximeter placed on the index finger of the left hand.
Values were recorded in beats per minute before and immediately after each repeated-sprint condition.
|
Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Peripheral Oxygen Saturation
Délai: Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
Peripheral oxygen saturation (SpO2) was measured using a Soulfix fingertip pulse oximeter placed on the index finger of the left hand.
Values were recorded as a percentage before and immediately after each repeated-sprint condition.
|
Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Systolic Blood Pressure
Délai: Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
Systolic blood pressure was measured on the left upper arm using an Omron M2 Essential automated digital blood-pressure monitor.
Values were recorded in millimeters of mercury (mmHg) before and immediately after each repeated-sprint condition.
|
Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Diastolic Blood Pressure
Délai: Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
Diastolic blood pressure was measured on the left upper arm using an Omron M2 Essential automated digital blood-pressure monitor.
Values were recorded in millimeters of mercury (mmHg) before and immediately after each repeated-sprint condition.
|
Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chercheur principal: Engin Güneş Atabaş, PhD, Pamukkale Üniversitesi
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
2 mai 2026
Achèvement primaire (Réel)
21 mai 2026
Achèvement de l'étude (Réel)
21 mai 2026
Dates d'inscription aux études
Première soumission
22 juillet 2026
Première soumission répondant aux critères de contrôle qualité
22 juillet 2026
Première publication (Réel)
27 juillet 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
30 juillet 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
29 juillet 2026
Dernière vérification
1 juillet 2026
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- PAU-COD-RSA-2026-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Description du régime IPD
Individual participant data will not be publicly shared because participant consent did not include public data sharing and the dataset contains information from adolescent participants.
De-identified aggregate data may be made available from the corresponding author upon reasonable request and subject to institutional and ethical approval.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .